Visual and morphological outcomes of bevacizumab (Avastin) versus ranibizumab (Lucentis) treatment for retinal angiomatous proliferation
International Ophthalmology, 04/25/2012Hufendiek K et al.
Patients with retinal angiomatous proliferation might benefit from both intravitreal bevacizumab and ranibizumab treatments with stabilization of visual acuity over a longer period of time. Close follow–up should nevertheless be performed in this special subgroup because of the high recurrence rate.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.